Opendata, web and dolomites

MicroTher SIGNED

MicroTher: Drug Discovery from the Microbiota

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "MicroTher" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI PERUGIA 

Organization address
address: PIAZZA DELL UNIVERSITA 1
city: PERUGIA
postcode: 6123
website: www.unipg.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 150˙000 €
 EC max contribution 150˙000 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2018-PoC
 Funding Scheme ERC-POC
 Starting year 2018
 Duration (year-month-day) from 2018-09-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI PERUGIA IT (PERUGIA) coordinator 150˙000.00

Map

 Project objective

The rapid increase in the prevalence of diseases caused by the disruption of the intestinal epithelium, also known as leaky gut syndrome, is a global cause for concern. Metabolic syndrome (MetSyn) and inflammatory bowel syndrome (IBS), two disease indications that occur as a result of a compromised intestinal mucosal membrane, collectively effect over 235 million people globally. In a healthy gut, the epithelial lining is tightly aligned to form a structurally robust barrier between the outside and the inside of the body. When this lining is compromised, immunogenic compounds such as bacterial endotoxins can infiltrate the body, causing systemic and local inflammation, resulting in diseases such as MetSyn and IBS. Through our ERC Advanced project FUNMETA, we have identified the ‘postbiotic’ molecule, indole-3-aldehyde (IAld), to be critical in the maintenance and restoration of intestinal epithelial integrity. Preliminary data already indicates the ability of IAld to repair damaged intestinal epithelium and to modulate symptoms of MetSyn and IBS in animal models. As these two indications are not only burdened by high prevalence rates, but also by ineffective or expensive treatments, there is strong potential in the clinical adoption of IAld. Therefore, the main aim of MicroTher is to further assess the clinical and commercial feasibility of IAld as a pharmaceutical agent.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "MICROTHER" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "MICROTHER" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

E-DIRECT (2020)

Evolution of Direct Reciprocity in Complex Environments

Read More  

REPLAY_DMN (2019)

A theory of global memory systems

Read More  

HYDROGEN (2019)

HighlY performing proton exchange membrane water electrolysers with reinforceD membRanes fOr efficient hydrogen GENeration

Read More